Printer Friendly

Trovagene Initiates First Clinical Site for Evaluation of PCM-075 in AML.

M2 PHARMA-November 14, 2017-Trovagene Initiates First Clinical Site for Evaluation of PCM-075 in AML

(C)2017 M2 COMMUNICATIONS

- San Diego, California-based molecular diagnostics company Trovagene, Inc. (NASDAQ: TROV) has activated its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with acute myeloid leukemia with Virginia Cancer Specialists, the company said.

This Phase 1b trial, a dose escalation study to determine a recommend phase 2 dose, will enroll subjects who have relapsed or have resistant disease to no more than three prior regimens.

The Phase 2 continuation study will provide preliminary evaluation of anti-leukemic activity and will enroll newly diagnosed subjects, judged to be ineligible for, or who have refused, standard intensive induction therapy, as well as subjects who have relapsed after treatment with no more than one prior regimen.

PCM-075, a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in multiple hematologic and solid tumor cancers, is oral, and has a 24-hour drug half-life with reversible on-target hematologic toxicities.

Trovagene believes that targeting only PLK1 with reversible on-target activity and an improved dose/scheduling protocol can significantly improve on the long-term outcome observed in previous studies with a PLK inhibitor in AML.

Trovagene is developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics.

The company has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.

Virginia Cancer Specialists is dedicated to the fight against cancer and diseases of the blood. The company's integrated treatment approach provides access to expanded services, including medical oncology and hematology, radiation therapy, breast surgery, orthopedic oncology and surgery, genetic counseling, palliative medicine and the only known dedicated oncology research facility in Northern Virginia to include Phase 1 clinical trials.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U5VA
Date:Nov 14, 2017
Words:329
Previous Article:Cardiff University develops new lymphoma treatment.
Next Article:RXi Pharmaceuticals Forms Research Collaboration with Gustave Roussy.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters